GeoVax Labs, Inc. presented positive interim Phase 2 clinical trial results for its COVID-19 vaccine candidate GEO-CM04S1 at the International Workshop on Chronic Lymphocytic Leukemia conference in Krakow, Poland. The data from trial NCT05672355 showed that the multi-antigen vaccine outperformed standard mRNA vaccines in patients with chronic lymphocytic leukemia, a blood cancer that leaves patients immunocompromised and vulnerable to COVID-19.
The study revealed that GEO-CM04S1 met the statistical requirements for the primary immune endpoint, while the mRNA comparator arm did not achieve this benchmark. Following this interim analysis and recommendation from the Data Safety Monitoring Board, enrollment has shifted exclusively to the GEO-CM04S1 arm. Both vaccines demonstrated favorable safety profiles with no grade 3 or higher adverse events reported.
David Dodd, Chairman and CEO of GeoVax, stated that these findings reinforce the value of their multi-antigen platform, emphasizing that immunocompromised patients have not been adequately protected by current vaccines. The company's vaccine represents both a clinical advancement and significant commercial opportunity in addressing this underserved patient population.
GEO-CM04S1 utilizes a Modified Vaccinia Ankara vector platform that encodes both the Spike and Nucleocapsid proteins of SARS-CoV-2, unlike first-generation vaccines that target only the Spike protein. This dual-antigen approach aims to provide broader, more durable immune protection against COVID-19 variants. The vaccine is currently being evaluated in three Phase 2 trials for various immunocompromised populations and as a booster in healthy adults.
The clinical success of GEO-CM04S1 has substantial implications for the millions of immunocompromised patients worldwide who remain vulnerable to COVID-19 despite vaccination. Current mRNA vaccines often provide insufficient protection for these high-risk individuals, creating a critical unmet medical need. GeoVax's technology platform positions the company to address this multi-billion dollar market segment where durable protection has remained elusive.
For additional information about GeoVax's clinical programs and technology platform, visit https://www.geovax.com. The original study details can be found through clinical trial identifier NCT05672355.
